Hypertension. A Companion to Braunwald's Heart Disease. Edition No. 4

Table of Contents

SECTION I: EPIDEMIOLOGY AND PREVENTIVE STRATEGIES 1. General Population and Global Cardiovascular Risk Prediction 2. Diet and Hypertension 3. Exercise and Hypertension 4. Hypertension in Women SECTION II: PATHOPHYSIOLOGY 5. Pathophysiology of Hypertension 6. Genetics of Hypertension 7. Inflammation and Immunity in Hypertension SECTION III: DIAGNOSIS AND EVALUATION 8. The Environment and High Blood Pressure 9. Office Blood Pressure Measurement 10. Home Monitoring of Blood Pressure 11. Ambulatory Blood Pressure Monitoring in Clinical Hypertension Management 12. White Coat and Masked Hypertension 13. Renovascular Hypertension and ISchemic Neuropathy 14. Secondary Hypertension: Primary Hyperaldosteronism and Mineralocorticoid Excess States 15. Secondary Hypertension: Pheochromocytoma and Paraganglioma 16. Sleep Disruption and Blood Pressure SECTION IV: RISK STRATIFICATION 17. The Natural History of Untreated Hypertension 18. Isolated Systolic Hypertension 19. Assessment of Hypertension-Mediated Organ Damage SECTION V: ANTIHYPERTENSIVE THERAPY 20. Diuretics Therapy 21. Calcium Channel Blockers 22. Renin Angiotensin Aldosterone System Blockers 23. Aldosterone and Hypertension 24. �-Blockers, Central Sympathetic Agents,and Direct Vasodilators 25. Peripheral Alpha Blockers 26. Initial Combination Therapies 27. Devices Therapies for Hypertension 28. The Treatment of Hypertension With Nutrition, Nutritional Supplements, and Lifestyle SECTION VI: HYPERTENSION MANAGEMENT APPROACHES 29. Approach to Difficult to Manage Primary Hypertension 30. Team-Based Care for Hypertension Management 31. Medication Adherence: Focus on Improvement 32. Digital Health and Telemedicine for Hypertension SECTION VII HYPERTENSION MANAGEMENT WITH COMORBIDITIES 33. Ischemic Heart Disease 34. Heart Failure 35. Hypertension and Chronic Kidney Disease Including Dialysis 36. Transplant Hypertension 37. Obesity and Hypertension: Pathophysiology and Treatment 38. Cerebrovascular Disease 39. Diabetes Mellitus: Management of Hypertension in Diabetes 40. Onco-Hypertension: Anticancer Therapy-Associated Hypertension 41. Autonomic Dysfunction and Orthostatic Hypotension 42. Dyslipidemia 43. Aorta and Peripheral Arterial Disease in Hypertension SECTION VIII SPECIAL POPULATIONS 44. Hypertension in Pregnancy 45. Hypertension in Older People 46. Hypertension in African Americans 47. Resistant Hypertension 48. Hypertensive Emergencies and Urgencies 49. Hypertension in Children: Diagnosis and Treatment Appendix Meta-Analyses of Blood Pressure Lowering Trials Index

Authors

George L. Bakris Professor of Medicine, Director, Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois. George L Bakris, MD, is a nephrologist whose specialty is kidney function/disease and hypertension. He has led several large NIH-funded studies resulting in paradigm shifts in blood pressure treatment guidelines for patients with treatable and challenging hypertension. Dr Bakris is Professor of Medicine and Director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago in Chicago, Illinois. Matthew Sorrentino Professor of Medicine, Associate Director, Bucksbaum Institute for Clinical Excellence, University of Chicago Medicine, Chicago, Illinois. Matthew J Sorrentino, MD, a cardiologist whose focus is preventive cardiology, is Professor of Medicine at the Bucksbaum Institute for Clinical Excellence and Vice Chair of Clinical Operations for the Department of Medicine at the University of Chicago. Both Drs Bakris and Sorrentino edited the current edition of Hypertension. Luke J. Laffin Co-Director, Center for Blood Pressure Disorders, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Luke J Laffin, MD, is Co-Director of the Center for Blood Pressure Disorders in the Department of Cardiovascular Medicine at Cleveland Clinic in Cleveland, Ohio. Dr Laffin was a contributor on the current edition.